{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:19:02Z","timestamp":1789499942023,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,16]],"date-time":"2023-04-16T00:00:00Z","timestamp":1681603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,16]],"date-time":"2023-04-16T00:00:00Z","timestamp":1681603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81720108033"],"award-info":[{"award-number":["81720108033"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82074019"],"award-info":[{"award-number":["82074019"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82274158"],"award-info":[{"award-number":["82274158"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Young Elite Scientists Sponsorship Program by CAST","award":["2021-QNRC2-B15"],"award-info":[{"award-number":["2021-QNRC2-B15"]}]},{"name":"Guangzhou Basic and Applied Basic Research Project","award":["202201011503"],"award-info":[{"award-number":["202201011503"]}]},{"name":"the open project of State Key Laboratory of Quality Research in Chinese Medicin","award":["MUST-SKL-2021-003"],"award-info":[{"award-number":["MUST-SKL-2021-003"]}]},{"name":"the open project of State Key Laboratory of Quality Research in Chinese Medicin","award":["2R2103"],"award-info":[{"award-number":["2R2103"]}]},{"DOI":"10.13039\/501100010883","name":"Administration of Traditional Chinese Medicine of Guangdong Province","doi-asserted-by":"crossref","award":["20222042"],"award-info":[{"award-number":["20222042"]}],"id":[{"id":"10.13039\/501100010883","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","award":["2020B1515130005"],"award-info":[{"award-number":["2020B1515130005"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]},{"name":"2020 Guangdong Provincial Science and Technology Innovation Strategy Special Fund","award":["2020B1212030006"],"award-info":[{"award-number":["2020B1212030006"]}]},{"name":"Shenzhen Virtual University Park (SZVUP) Special Fund Project","award":["2021Szvup131"],"award-info":[{"award-number":["2021Szvup131"]}]},{"name":"FNRA-IG","award":["RC-FNRA-IG\/20-21\/SCM\/01"],"award-info":[{"award-number":["RC-FNRA-IG\/20-21\/SCM\/01"]}]},{"name":"ITC","award":["PRP\/015\/19FX"],"award-info":[{"award-number":["PRP\/015\/19FX"]}]},{"name":"GDNSF","award":["2021A1515010655"],"award-info":[{"award-number":["2021A1515010655"]}]},{"DOI":"10.13039\/501100005847","name":"HMRF","doi-asserted-by":"crossref","award":["08193596"],"award-info":[{"award-number":["08193596"]}],"id":[{"id":"10.13039\/501100005847","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>More than half of the colorectal cancer (CRC) patients will develop liver metastasis that underlies the cancer mortality. In the hepatic tumor microenvironment, the interplay between CRC cells and hepatic stellate cells (HSCs), and the activation of HSCs to become carcinoma-associated fibroblasts (CAFs) will further promote the cancer development. Nevertheless, the critical signaling molecule that involved in these processes remains unknown, which hinders the development of effective therapeutic agents for the treatment of metastatic CRC (mCRC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Conditioned medium system and co-cultured system were used to examine the interplay between CRC cells and HSCs. Luminex liquid suspension chip detection and enzyme-linked immunosorbent assay were used to screen for the mediators in the conditioned medium that facilitated the CRC-HSCs interplay and HSCs-to-CAFs differentiation. Cell and animal models were used to examine whether brevilin A inhibited CRC liver metastasis via the VEGF-IL6-STAT3 axis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In the CRC-HSCs interplay, CRC promoted HSCs-to-CAFs differentiation by releasing vascular endothelial growth factor (VEGF); and HSCs released interleukin 6 (IL6) that activated signal transducer and activator of transcription 3 (STAT3) in the CRC and hence increased the cancer metastatic potential. The functions of the VEGF-IL6-STAT3 axis in the HSCs-CRC interplay were further validated by VEGF recombinant protein and IL6 neutralizing antibody. More importantly, brevilin A, an active compound isolated from <jats:italic>Centipeda minima<\/jats:italic> (L.) A. Br. et Aschers, targeted the VEGF-IL6-STAT3 axis in the CRC-HSCs interplay, hence significantly inhibited colorectal liver metastasis and cancer growth both in vitro and in vivo.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We are the first to demonstrate brevilin A possesses potent anti-mCRC effect by targeting the VEGF-IL6-STAT3 axis in the CRC-HSCs interplay. Our findings not only support the development of brevilin A as a novel therapeutic agent for mCRC treatment, but also pave the path for the development of other VEGF-IL6-STAT3 targeting therapeutic strategies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12967-023-04087-6","type":"journal-article","created":{"date-parts":[[2023,4,16]],"date-time":"2023-04-16T10:02:03Z","timestamp":1681639323000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Brevilin A is a potent anti-metastatic CRC agent that targets the VEGF-IL6-STAT3 axis in the HSCs-CRC interplay"],"prefix":"10.1186","volume":"21","author":[{"given":"Xueying","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjing","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jincheng","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilin","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiu-Yee","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongqiu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,16]]},"reference":[{"issue":"8","key":"4087_CR1","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrc865","volume":"2","author":"AF Chambers","year":"2002","unstructured":"Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2(8):563\u201372.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"4087_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"4087_CR3","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1093\/annonc\/mdt591","volume":"25","author":"N Hugen","year":"2014","unstructured":"Hugen N, van de Velde CJH, de Wilt JHW, Nagtegaal ID. Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. Ann Oncol. 2014;25(3):651\u20137.","journal-title":"Ann Oncol"},{"issue":"10","key":"4087_CR4","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/nrc2229","volume":"7","author":"E Sahai","year":"2007","unstructured":"Sahai E. Illuminating the metastatic process. Nat Rev Cancer. 2007;7(10):737\u201349.","journal-title":"Nat Rev Cancer"},{"issue":"24","key":"4087_CR5","doi-asserted-by":"publisher","first-page":"5971","DOI":"10.1158\/1078-0432.CCR-16-0460","volume":"22","author":"P Brodt","year":"2016","unstructured":"Brodt P. Role of the microenvironment in liver metastasis: from pre- to prometastatic niches. Clin Cancer Res. 2016;22(24):5971\u201382.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4087_CR6","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-018-0858-1","volume":"17","author":"B Ren","year":"2018","unstructured":"Ren B, Cui M, Yang G, Wang H, Feng M, You L, et al. Tumor microenvironment participates in metastasis of pancreatic cancer. Mol Cancer. 2018;17(1):108.","journal-title":"Mol Cancer"},{"issue":"5","key":"4087_CR7","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.2353\/ajpath.2007.060661","volume":"171","author":"L Mueller","year":"2007","unstructured":"Mueller L, Goumas FA, Affeldt M, Sandtner S, Gehling UM, Brilloff S, et al. Stromal fibroblasts in colorectal liver metastases originate from resident fibroblasts and generate an inflammatory microenvironment. Am J Pathol. 2007;171(5):1608\u201318.","journal-title":"Am J Pathol"},{"issue":"21","key":"4087_CR8","doi-asserted-by":"publisher","first-page":"5914","DOI":"10.1158\/1078-0432.CCR-13-0694","volume":"19","author":"M Herrera","year":"2013","unstructured":"Herrera M, Islam AB, Herrera A, Martin P, Garcia V, Silva J, et al. Functional heterogeneity of cancer-associated fibroblasts from human colon tumors shows specific prognostic gene expression signature. Clin Cancer Res. 2013;19(21):5914\u201326.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4087_CR9","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/hep.24384","volume":"54","author":"N Kang","year":"2011","unstructured":"Kang N, Gores GJ, Shah VH. Hepatic stellate cells: partners in crime for liver metastases? Hepatology. 2011;54(2):707\u201313.","journal-title":"Hepatology"},{"issue":"1","key":"4087_CR10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/onc.2012.536","volume":"33","author":"LJ Hawinkels","year":"2014","unstructured":"Hawinkels LJ, Paauwe M, Verspaget HW, Wiercinska E, van der Zon JM, van der Ploeg K, et al. Interaction with colon cancer cells hyperactivates TGF-beta signaling in cancer-associated fibroblasts. Oncogene. 2014;33(1):97\u2013107.","journal-title":"Oncogene"},{"issue":"9","key":"4087_CR11","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1245\/s10434-009-0599-x","volume":"16","author":"R Matsusue","year":"2009","unstructured":"Matsusue R, Kubo H, Hisamori S, Okoshi K, Takagi H, Hida K, et al. Hepatic stellate cells promote liver metastasis of colon cancer cells by the action of SDF-1\/CXCR4 axis. Ann Surg Oncol. 2009;16(9):2645\u201353.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"4087_CR12","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1080\/15384047.2019.1685157","volume":"21","author":"HX Tan","year":"2020","unstructured":"Tan HX, Gong WZ, Zhou K, Xiao ZG, Hou FT, Huang T, et al. CXCR4\/TGF-beta1 mediated hepatic stellate cells differentiation into carcinoma-associated fibroblasts and promoted liver metastasis of colon cancer. Cancer Biol Ther. 2020;21(3):258\u201368.","journal-title":"Cancer Biol Ther"},{"issue":"4","key":"4087_CR13","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/ijc.25725","volume":"128","author":"LD Nagaprashantha","year":"2011","unstructured":"Nagaprashantha LD, Vatsyayan R, Lelsani PC, Awasthi S, Singhal SS. The sensors and regulators of cell-matrix surveillance in anoikis resistance of tumors. Int J Cancer. 2011;128(4):743\u201352.","journal-title":"Int J Cancer"},{"issue":"10","key":"4087_CR14","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/nrd3266","volume":"9","author":"D Cox","year":"2010","unstructured":"Cox D, Brennan M, Moran N. Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov. 2010;9(10):804\u201320.","journal-title":"Nat Rev Drug Discov"},{"issue":"37","key":"4087_CR15","doi-asserted-by":"publisher","first-page":"4821","DOI":"10.1038\/onc.2014.410","volume":"34","author":"CE Weber","year":"2015","unstructured":"Weber CE, Kothari AN, Wai PY, Li NY, Driver J, Zapf MA, et al. Osteopontin mediates an MZF1-TGF-beta1-dependent transformation of mesenchymal stem cells into cancer-associated fibroblasts in breast cancer. Oncogene. 2015;34(37):4821\u201333.","journal-title":"Oncogene"},{"issue":"10","key":"4087_CR16","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.annonc.2020.07.009","volume":"31","author":"D Ciardiello","year":"2020","unstructured":"Ciardiello D, Elez E, Tabernero J, Seoane J. Clinical development of therapies targeting TGF\u03b2: current knowledge and future perspectives. Ann Oncol. 2020;31(10):1336\u201349.","journal-title":"Ann Oncol"},{"issue":"12","key":"4087_CR17","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1111\/j.1349-7006.2000.tb00916.x","volume":"91","author":"S Shimizu","year":"2000","unstructured":"Shimizu S, Yamada N, Sawada T, Ikeda K, Kawada N, Seki S, et al. In vivo and in vitro interactions between human colon carcinoma cells and hepatic stellate cells. Jpn J Cancer Res. 2000;91(12):1285\u201395.","journal-title":"Jpn J Cancer Res"},{"key":"4087_CR18","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3389\/fphar.2019.00594","volume":"10","author":"R Liu","year":"2019","unstructured":"Liu R, Qu Z, Lin Y, Lee CS, Tai WC, Chen S. Brevilin A induces cell cycle arrest and apoptosis in nasopharyngeal carcinoma. Front Pharmacol. 2019;10:594.","journal-title":"Front Pharmacol"},{"key":"4087_CR19","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.biopha.2017.12.057","volume":"98","author":"P You","year":"2018","unstructured":"You P, Wu H, Deng M, Peng J, Li F, Yang Y. Brevilin A induces apoptosis and autophagy of colon adenocarcinoma cell CT26 via mitochondrial pathway and PI3K\/AKT\/mTOR inactivation. Biomed Pharmacother. 2018;98:619\u201325.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"4087_CR20","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.3390\/ijms22031052","volume":"22","author":"Y Kim","year":"2021","unstructured":"Kim Y, Sengupta S, Sim T. Natural and synthetic lactones possessing antitumor activities. Int J Mol Sci. 2021;22(3):1052.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4087_CR21","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/icb.2016.109","volume":"95","author":"J Luo","year":"2017","unstructured":"Luo J, Liang Y, Kong F, Qiu J, Liu X, Chen A, et al. Vascular endothelial growth factor promotes the activation of hepatic stellate cells in chronic schistosomiasis. Immunol Cell Biol. 2017;95(4):399\u2013407.","journal-title":"Immunol Cell Biol"},{"issue":"4","key":"4087_CR22","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson DE, O\u2019Keefe RA, Grandis JR. Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15(4):234\u201348.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"4087_CR23","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.3390\/biomedicines9081016","volume":"9","author":"AN Gargalionis","year":"2021","unstructured":"Gargalionis AN, Papavassiliou KA, Papavassiliou AG. Targeting STAT3 signaling pathway in colorectal cancer. Biomedicines. 2021;9(8):1016.","journal-title":"Biomedicines."},{"issue":"5","key":"4087_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063697","volume":"8","author":"X Chen","year":"2013","unstructured":"Chen X, Du Y, Nan J, Zhang X, Qin X, Wang Y, et al. Brevilin A, a novel natural product, inhibits janus kinase activity and blocks STAT3 signaling in cancer cells. PLoS One. 2013;8(5): e63697.","journal-title":"PLoS One"},{"issue":"6","key":"4087_CR25","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1593\/neo.04571","volume":"7","author":"FM Corvinus","year":"2005","unstructured":"Corvinus FM, Orth C, Moriggl R, Tsareva SA, Wagner S, Pfitzner EB, et al. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia. 2005;7(6):545\u201355.","journal-title":"Neoplasia"},{"issue":"8","key":"4087_CR26","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1111\/j.1582-4934.2011.01483.x","volume":"16","author":"W Du","year":"2012","unstructured":"Du W, Hong J, Wang YC, Zhang YJ, Wang P, Su WY, et al. Inhibition of JAK2\/STAT3 signalling induces colorectal cancer cell apoptosis via mitochondrial pathway. J Cell Mol Med. 2012;16(8):1878\u201388.","journal-title":"J Cell Mol Med"},{"issue":"10","key":"4087_CR27","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/onc.2010.496","volume":"30","author":"S Samuel","year":"2011","unstructured":"Samuel S, Fan F, Dang LH, Xia L, Gaur P, Ellis LM. Intracrine vascular endothelial growth factor signaling in survival and chemoresistance of human colorectal cancer cells. Oncogene. 2011;30(10):1205\u201312.","journal-title":"Oncogene"},{"issue":"9","key":"4087_CR28","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1093\/jjco\/hyp066","volume":"39","author":"NT Okita","year":"2009","unstructured":"Okita NT, Yamada Y, Takahari D, Hirashima Y, Matsubara J, Kato K, et al. Vascular endothelial growth factor receptor expression as a prognostic marker for survival in colorectal cancer. Jpn J Clin Oncol. 2009;39(9):595\u2013600.","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"4087_CR29","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/bjc.2017.238","volume":"117","author":"R Bhattacharya","year":"2017","unstructured":"Bhattacharya R, Fan F, Wang R, Ye X, Xia L, Boulbes D, et al. Intracrine VEGF signalling mediates colorectal cancer cell migration and invasion. Br J Cancer. 2017;117(6):848\u201355.","journal-title":"Br J Cancer"},{"issue":"11","key":"4087_CR30","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1038\/s41401-022-00907-5","volume":"43","author":"H Shen","year":"2022","unstructured":"Shen H, Yu H, Li QY, Wei YT, Fu J, Dong H, et al. Hepatocyte-derived VEGFA accelerates the progression of non-alcoholic fatty liver disease to hepatocellular carcinoma via activating hepatic stellate cells. Acta Pharmacol Sin. 2022;43(11):2917\u201328.","journal-title":"Acta Pharmacol Sin"},{"issue":"5B","key":"4087_CR31","first-page":"3905","volume":"26","author":"YC Chung","year":"2006","unstructured":"Chung YC, Chaen YL, Hsu CP. Clinical significance of tissue expression of interleukin-6 in colorectal carcinoma. Anticancer Res. 2006;26(5B):3905\u201311.","journal-title":"Anticancer Res"},{"issue":"4","key":"4087_CR32","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/jso.10269","volume":"83","author":"YC Chung","year":"2003","unstructured":"Chung YC, Chang YF. Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol. 2003;83(4):222\u20136.","journal-title":"J Surg Oncol"},{"issue":"1","key":"4087_CR33","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.canlet.2005.12.003","volume":"244","author":"F Esfandi","year":"2006","unstructured":"Esfandi F, MohammadzadehGhobadloo S, Basati G. Interleukin-6 level in patients with colorectal cancer. Cancer Lett. 2006;244(1):76\u20138.","journal-title":"Cancer Lett"},{"issue":"17","key":"4087_CR34","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.1158\/0008-5472.CAN-17-2268","volume":"78","author":"TA Karakasheva","year":"2018","unstructured":"Karakasheva TA, Lin EW, Tang Q, Qiao E, Waldron TJ, Soni M, et al. IL-6 mediates cross-talk between tumor cells and activated fibroblasts in the tumor microenvironment. Cancer Res. 2018;78(17):4957\u201370.","journal-title":"Cancer Res"},{"issue":"54","key":"4087_CR35","first-page":"1910","volume":"50","author":"YC Chung","year":"2003","unstructured":"Chung YC, Chang YF. Significance of inflammatory cytokines in the progression of colorectal cancer. Hepatogastroenterology. 2003;50(54):1910\u20133.","journal-title":"Hepatogastroenterology"},{"issue":"12","key":"4087_CR36","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1158\/2326-6066.CIR-18-0766","volume":"7","author":"Y Toyoshima","year":"2019","unstructured":"Toyoshima Y, Kitamura H, Xiang H, Ohno Y, Homma S, Kawamura H, et al. IL6 modulates the immune status of the tumor microenvironment to facilitate metastatic colonization of colorectal cancer cells. Cancer Immunol Res. 2019;7(12):1944\u201357.","journal-title":"Cancer Immunol Res"},{"key":"4087_CR37","doi-asserted-by":"publisher","first-page":"8032187","DOI":"10.1155\/2020\/8032187","volume":"2020","author":"Q Sun","year":"2020","unstructured":"Sun Q, Shang Y, Sun F, Dong X, Niu J, Li F. Interleukin-6 promotes epithelial-mesenchymal transition and cell invasion through integrin beta6 upregulation in colorectal cancer. Oxid Med Cell Longev. 2020;2020:8032187.","journal-title":"Oxid Med Cell Longev"},{"issue":"4","key":"4087_CR38","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1111\/j.1349-7006.2009.01087.x","volume":"100","author":"T Amann","year":"2009","unstructured":"Amann T, Bataille F, Spruss T, Muhlbauer M, Gabele E, Scholmerich J, et al. Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci. 2009;100(4):646\u201353.","journal-title":"Cancer Sci"},{"issue":"4","key":"4087_CR39","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s00595-016-1404-7","volume":"47","author":"M Hara","year":"2017","unstructured":"Hara M, Nagasaki T, Shiga K, Takahashi H, Takeyama H. High serum levels of interleukin-6 in patients with advanced or metastatic colorectal cancer: the effect on the outcome and the response to chemotherapy plus bevacizumab. Surg Today. 2017;47(4):483\u20139.","journal-title":"Surg Today"},{"issue":"10","key":"4087_CR40","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a016295","volume":"6","author":"T Tanaka","year":"2014","unstructured":"Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6(10): a016295.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"2","key":"4087_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0149154","volume":"11","author":"B Shulgin","year":"2016","unstructured":"Shulgin B, Helmlinger G, Kosinsky Y. A generic mechanism for enhanced cytokine signaling via cytokine-neutralizing antibodies. PLoS ONE. 2016;11(2): e0149154.","journal-title":"PLoS ONE"},{"issue":"6","key":"4087_CR42","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1177\/2040620716653745","volume":"7","author":"S Sarosiek","year":"2016","unstructured":"Sarosiek S, Shah R, Munshi NC. Review of siltuximab in the treatment of multicentric Castleman\u2019s disease. Ther Adv Hematol. 2016;7(6):360\u20136.","journal-title":"Ther Adv Hematol"},{"issue":"8","key":"4087_CR43","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1158\/1078-0432.CCR-13-2200","volume":"20","author":"E Angevin","year":"2014","unstructured":"Angevin E, Tabernero J, Elez E, Cohen SJ, Bahleda R, van Laethem JL, et al. A phase I\/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res. 2014;20(8):2192\u2013204.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4087_CR44","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.molonc.2015.02.012","volume":"9","author":"L Brambilla","year":"2015","unstructured":"Brambilla L, Genini D, Laurini E, Merulla J, Perez L, Fermeglia M, et al. Hitting the right spot: mechanism of action of OPB-31121, a novel and potent inhibitor of the signal transducer and activator of transcription 3 (STAT3). Mol Oncol. 2015;9(6):1194\u2013206.","journal-title":"Mol Oncol"},{"issue":"4","key":"4087_CR45","doi-asserted-by":"publisher","first-page":"607","DOI":"10.4143\/crt.2014.249","volume":"47","author":"DY Oh","year":"2015","unstructured":"Oh DY, Lee SH, Han SW, Kim MJ, Kim TM, Kim TY, et al. Phase I study of OPB-31121, an oral STAT3 Inhibitor, in patients with advanced solid tumors. Cancer Res Treat. 2015;47(4):607\u201315.","journal-title":"Cancer Res Treat"},{"issue":"11","key":"4087_CR46","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.3390\/cancers11111681","volume":"11","author":"YK Lau","year":"2019","unstructured":"Lau YK, Ramaiyer M, Johnson DE, Grandis JR. Targeting STAT3 in cancer with nucleotide therapeutics. Cancers. 2019;11(11):1681.","journal-title":"Cancers"},{"issue":"10","key":"4087_CR47","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1038\/s41388-018-0547-y","volume":"38","author":"N Wei","year":"2019","unstructured":"Wei N, Li J, Fang C, Chang J, Xirou V, Syrigos NK, et al. Targeting colon cancer with the novel STAT3 inhibitor bruceantinol. Oncogene. 2019;38(10):1676\u201387.","journal-title":"Oncogene"},{"issue":"4","key":"4087_CR48","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1359-6101(98)80005-1","volume":"8","author":"T Hirano","year":"1997","unstructured":"Hirano T, Nakajima K, Hibi M. Signaling mechanisms through gp130: a model of the cytokine system. Cytokine Growth Factor Rev. 1997;8(4):241\u201352.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"3","key":"4087_CR49","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/jcb.20477","volume":"95","author":"Z Culig","year":"2005","unstructured":"Culig Z, Steiner H, Bartsch G, Hobisch A. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem. 2005;95(3):497\u2013505.","journal-title":"J Cell Biochem"},{"issue":"11","key":"4087_CR50","doi-asserted-by":"publisher","first-page":"4827","DOI":"10.1158\/0008-5472.CAN-05-0188","volume":"65","author":"JL Su","year":"2005","unstructured":"Su JL, Lai KP, Chen CA, Yang CY, Chen PS, Chang CC, et al. A novel peptide specifically binding to interleukin-6 receptor (gp80) inhibits angiogenesis and tumor growth. Cancer Res. 2005;65(11):4827\u201335.","journal-title":"Cancer Res"},{"issue":"24","key":"4087_CR51","doi-asserted-by":"publisher","first-page":"14586","DOI":"10.1021\/acsomega.0c01276","volume":"5","author":"MM Lee","year":"2020","unstructured":"Lee MM, Chan BD, Wong WY, Leung TW, Qu Z, Huang J, et al. Synthesis and evaluation of novel anticancer compounds derived from the natural product brevilin A. ACS Omega. 2020;5(24):14586\u201396.","journal-title":"ACS Omega"},{"key":"4087_CR52","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.3389\/fphar.2020.01297","volume":"11","author":"M Piesche","year":"2020","unstructured":"Piesche M, Roos J, Kuhn B, Fettel J, Hellmuth N, Brat C, et al. The emerging therapeutic potential of nitro fatty acids and other michael acceptor-containing drugs for the treatment of inflammation and cancer. Front Pharmacol. 2020;11:1297.","journal-title":"Front Pharmacol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04087-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-023-04087-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04087-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,16]],"date-time":"2023-04-16T11:02:55Z","timestamp":1681642975000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-023-04087-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,16]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4087"],"URL":"https:\/\/doi.org\/10.1186\/s12967-023-04087-6","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,16]]},"assertion":[{"value":"6 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were conducted in accordance with the principles and procedures approved by the Committee on the Ethics of Animal Experiments of Guangzhou University of traditional Chinese Medicine (No. 20200328021).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"260"}}